Establishment of a Plasticity-Associated Risk Model Based on a SOX2- and SOX9-Related Gene Set in Head and Neck Squamous Cell Carcinoma

• Published in: Molecular cancer research 2021-10, Vol.19 (10), p.1676-1687
• Main Authors: Khorani, Karam, Schwaerzler, Julia, Burkart, Sebastian, Kurth, Ina, Holzinger, Dana, Flechtenmacher, Christa, Plinkert, Peter K, Zaoui, Karim, Hess, Jochen
• Format: Article
• Language: English
• Subjects: Carcinogenesis - genetics; Cell Line, Tumor; Cohort Studies; Gene Expression Regulation, Neoplastic - genetics; Head and Neck Neoplasms - genetics; Humans; Oncogenes - genetics; Prognosis; Signal Transduction - genetics; SOX9 Transcription Factor - genetics; SOXB1 Transcription Factors - genetics; Squamous Cell Carcinoma of Head and Neck - genetics; Up-Regulation - genetics
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.MCR-21-0066

Recent studies highlighted SOX2 and SOX9 as key determinants for cancer-cell plasticity and demonstrated that cisplatin-induced adaptation in oral squamous cell carcinoma (SCC) is acquired by an inverse regulation of both transcription factors. However, the association between SOX2/SOX9-related genetic programs with risk factors and genetic or epigenetic alterations in primary head and neck SCC (HNSCC), and their prognostic value is largely unknown.Here, we identified differentially-expressed genes (DEG) related to SOX2 and SOX9 transcription in The Cancer Genome Atlas (TCGA)-HNSC, which enable clustering of patients into groups with distinct clinical features and survival. A prognostic risk model was established by LASSO Cox regression based on expression patterns of DEGs in TCGA-HNSC (training cohort), and was confirmed in independent HNSCC validation cohorts as well as other cancer cohorts from TCGA. Differences in the mutational landscape among risk groups of TCGA-HNSC demonstrated an enrichment of truncating mutations for the low-risk group and elucidated DNA methylation as modulator of SOX2 expression. Gene set variation analysis (GSVA) revealed differences in several oncogenic pathways among risk groups, including upregulation of gene sets related to oncogenic KRAS signaling for the high-risk group. Finally, drug screen analysis revealed numerous compounds targeting EGFR signaling with significantly lower efficacy for cancer cell lines with a higher risk phenotype, but also indicated potential vulnerabilities. IMPLICATIONS: The established risk model identifies patients with primary HNSCC, but also other cancers at a higher risk for treatment failure, who might benefit from a therapy targeting SOX2/SOX9-related gene regulatory and signaling networks.